Pitfalls and Caveats in BRCA Sequencing

作者: Beatriz Bellosillo , Ignacio Tusquets

DOI: 10.1080/01913120500521281

关键词:

摘要: Between 5 and 10% of breast cancer cases are considered to result from hereditary predisposition. Germ-line mutations in BRCA1 BRCA2 responsible for an inherited predisposition ovarian cancer. Direct nucleotide sequencing is the gold standard technique mutation detection genes such as BRCA2. In many laboratories that analyze BRCA2, previous direct sequencing, screening techniques identify sequence variants PCR amplicons performed. The detected these may be frameshift (insertions or deletions), nonsense mutations, missense mutations. clinical interpretation cause disease difficult establish case Only 30-70% families which a component suspected, and/or detected. Negative results due to: wrong selection proband; regulatory portion genes; gene silencing epigenetic phenomena; large genomic rearrangements produce deletions whole exons. Another possibility explains lack alterations presence undiscovered interact with low-penetrance genes, like CHEK2.

参考文章(64)
Jacques Estève, Michel Coleman, Trends in cancer incidence and mortality IARC scientific publications. pp. 1- 806 ,(1993) , 10.3109/9780415874984-2
Elizabeth L. Schubert, Jamie L. Dann, Jan E. Morrow, Mary Claire King, Ming K. Lee, Judy Hull, Rhodora H. Argonza, Heather C. Mefford, BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2 American Journal of Human Genetics. ,vol. 60, pp. 1031- 1040 ,(1997)
Kenneth Offit, Heather Pierce, Tomas Kirchhoff, Prema Kolachana, Beth Rapaport, Peter Gregersen, Steven Johnson, Orit Yossepowitch, Helen Huang, Jaya Satagopan, Mark Robson, Lauren Scheuer, Khedoudja Nafa, Nathan Ellis, Frequency of CHEK2*1100delC in New York breast cancer cases and controls BMC Medical Genetics. ,vol. 4, pp. 1- 4 ,(2003) , 10.1186/1471-2350-4-1
Steven A. Narod, Gilbert M. Lenoir, David Goldgar, Patricia Tonin, Sylvie Mazoyer, Yin Y. Shugart, Henry T. Lynch, Nadine Puget, Olga M. Serova, Valérie Dubois, Mutations in BRCA1 and BRCA2 in breast cancer families: Are there more breast cancer-susceptibility genes? American Journal of Human Genetics. ,vol. 60, pp. 486- 495 ,(1997)
Sharon B. Cantor, Ralph Scully, Daniel P. Silver, Junjie Chen, David M. Livingston, BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Research. ,vol. 59, ,(1999)
Wen-Hwa Lee, Andrew A. Farmer, Diane C. Jones, Phang-Lang Chen, Yumay Chen, Chi-Fen Chen, BRCA1 Is a 220-kDa Nuclear Phosphoprotein That Is Expressed and Phosphorylated in a Cell Cycle-dependent Manner Cancer Research. ,vol. 56, pp. 3168- 3172 ,(1996)
N Dahl, E Holmberg, U Kristoffersson, O Johannsson, A M Gerdes, G Sellberg, N Pandis, Sara Hakansson, Åke Borg, Håkan Olsson, Ulla Johansson, N Loman, Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer American Journal of Human Genetics. ,vol. 60, pp. 1068- 1078 ,(1997)
Jennifer L. Kelsey, Breast Cancer Epidemiology: Summary and Future Directions Epidemiologic Reviews. ,vol. 15, pp. 256- 263 ,(1993) , 10.1093/OXFORDJOURNALS.EPIREV.A036112
Wera Hofmann, Heike Görgens, Anika John, Denise Horn, Christine Hüttner, Norbert Arnold, Siegfried Scherneck, Hans K. Schackert, Screening for large rearrangements of theBRCA1gene in German breast or ovarian cancer families using semi-quantitative multiplex PCR method Human Mutation. ,vol. 22, pp. 103- 104 ,(2003) , 10.1002/HUMU.9154
Ralph Scully, Junjie Chen, Annemieke Plug, Yonghong Xiao, David Weaver, Jean Feunteun, Terry Ashley, David M Livingston, Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells Cell. ,vol. 88, pp. 265- 275 ,(1997) , 10.1016/S0092-8674(00)81847-4